Shoshana Sztal-Mazer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shoshana Sztal-Mazer has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Aviva Frydman
Department of Endocrinology & Diabetes, Western Health, Melbourne, Australia
3 shared publications- Elif Ilhan Ekinci
Australian Centre for Accelerating Diabetes Innovations (ACADI) The University of Melbourne Melbourne Victoria Australia
3 shared publications - Leon A. Bach
Department of Endocrinology and Diabetes, The Alfred, Melbourne, Victoria, Australia
3 shared publications Mark Ng
Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
3 shared publications- Peter Shane Hamblin
School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
3 shared publications - Raymond Hu
Department of Anaesthesia, Austin Health, Heidelberg, Victoria, Australia
3 shared publications
Latest Publications
- Open Access
- 16 April 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Asian ethnicity is associated with shorter antiresorptive exposure prior to atypical femur fracture (AFF): a Transcontinental Atypical Femoral Fracture Consortium (TrAFFiC) cohort study
Osteoporosis prevalence is expected to increase with global aging. Bisphosphonates and denosumab are effective treatments, but anxiety regarding safety concerns, medication-related osteonecrosis of the jaw and atypical femur fractures (AFFs), have contributed to a decline in bisphosphonate use in recent years. The Transcontinental Atypical Femoral Fracture Consortium (TrAFFiC) was established to identify potential higher risk clinical factors contributing to AFF development. Within TrAFFiC, an AFF registry was established. One hundred and sixty-six patients with AFFs were included. Seventy-seven (46%) patients sustained bilateral AFFs, totaling 243 AFFs (138 complete and 105 incomplete). Sixty-two (37%) individuals were of Asian ethnicity, with 40 (24%) specifically of Southeast Asian ethnicity. Comparisons within this AFF cohort revealed that Asian individuals were shorter and lower weight (152.0 cm vs 154.6 cm, p < .038; 57.5 kg vs 66.8 kg, p < .001) than non-Asian peers and were less likely to have a history of minimal trauma fractures prior to AFF (53% vs 84%, p < .001). Asian ethnicity [OR 2.10 (95% CI 1.06, 4.02), p = .034] and Southeast Asian ethnicity [OR 3.25 (95% CI 1.55, 6.8), p = .002] were associated with an increased likelihood of “earlier onset” AFF development, that is, an AFF sustained following ≤5 yr of antiresorptive treatment. Lastly, teriparatide use following incomplete AFF (n = 34) did not affect time to healing or pain resolution. In conclusion, Asian individuals sustained AFFs following a shorter duration of antiresorptive treatment compared with non-Asian AFF peers. In addition, Asian individuals were less likely to sustain additional minimal trauma fractures. While assessment for a drug holiday may be appropriate for patients at lower risk of AFF after 5 yr of oral antiresorptive treatment, in those with risk factors for “earlier onset” AFF, further research is required to guide whether a lower dose or shorter duration of treatment or prioritization of bone anabolic treatments should be considered.
- 16 April 2026
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
Open AccessAsian ethnicity is associated with shorter antiresorptive exposure prior to atypical femur fracture (AFF): a Transcontinental Atypical Femoral Fracture Consortium (TrAFFiC) cohort study
Osteoporosis prevalence is expected to increase with global aging. Bisphosphonates and denosumab are effective treatments, but anxiety regarding safety concerns, medication-related osteonecrosis of the jaw and atypical femur fractures (AFFs), have contributed to a decline in bisphosphonate use in recent years. The Transcontinental Atypical Femoral Fracture Consortium (TrAFFiC) was established to identify potential higher risk clinical factors contributing to AFF development. Within TrAFFiC, an AFF registry was established. One hundred and sixty-six patients with AFFs were included. Seventy-seven (46%) patients sustained bilateral AFFs, totaling 243 AFFs (138 complete and 105 incomplete). Sixty-two (37%) individuals were of Asian ethnicity, with 40 (24%) specifically of Southeast Asian ethnicity. Comparisons within this AFF cohort revealed that Asian individuals were shorter and lower weight (152.0 cm vs 154.6 cm, p < .038; 57.5 kg vs 66.8 kg, p < .001) than non-Asian peers and were less likely to have a history of minimal trauma fractures prior to AFF (53% vs 84%, p < .001). Asian ethnicity [OR 2.10 (95% CI 1.06, 4.02), p = .034] and Southeast Asian ethnicity [OR 3.25 (95% CI 1.55, 6.8), p = .002] were associated with an increased likelihood of “earlier onset” AFF development, that is, an AFF sustained following ≤5 yr of antiresorptive treatment. Lastly, teriparatide use following incomplete AFF (n = 34) did not affect time to healing or pain resolution. In conclusion, Asian individuals sustained AFFs following a shorter duration of antiresorptive treatment compared with non-Asian AFF peers. In addition, Asian individuals were less likely to sustain additional minimal trauma fractures. While assessment for a drug holiday may be appropriate for patients at lower risk of AFF after 5 yr of oral antiresorptive treatment, in those with risk factors for “earlier onset” AFF, further research is required to guide whether a lower dose or shorter duration of treatment or prioritization of bone anabolic treatments should be considered.
- Open Access
Incidence, prevalence, and predictors of osteoporotic fracture in adult lung transplant recipients
- 6 June 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (9) , e3964
Letter to the Editor From Danek et al: “Environmental Pollution, Climate Change, and a Critical Role for the Endocrinologist”
Eleanor T Danek, MBBS(hons) BMedSc(hons), Diana Blackburn, BNurse Grad Cert Diab Edu, Duncan J Topliss, MD FRACP FACE, Shoshana Sztal-Mazer, MBBS(hons) FRACP; L
- 6 June 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (9) , e3964
Letter to the Editor From Danek et al: “Environmental Pollution, Climate Change, and a Critical Role for the Endocrinologist”
Eleanor T Danek, MBBS(hons) BMedSc(hons), Diana Blackburn, BNurse Grad Cert Diab Edu, Duncan J Topliss, MD FRACP FACE, Shoshana Sztal-Mazer, MBBS(hons) FRACP; L
- Open Access
- 22 February 2022
- Published by Wiley in Clinical Endocrinology
- Vol. 98 (5) , 643-648
How to manage Graves’ disease in women of childbearing potential
The management of Graves’ disease (GD) in women of childbearing potential has multiple specific complexities. Many factors are involved, which differ at the various stages from preconception, conception, first trimester, later pregnancy, postpartum and lactation, with both maternal and foetal considerations. The incidence and significance of the risks incurred from antithyroid drugs (ATDs) in pregnancy have been re‐evaluated recently and must be balanced against the risks of uncontrolled hyperthyroidism during childbearing years. Contraception is advised until hyperthyroidism is controlled. ATD cessation should be considered in those who are well controlled on low dose therapy before conception and in early pregnancy. Advice on iodine supplementation does not generally differ in those with GD. Radioiodine (RAI) is contraindicated from 6 months preconception until completion of breastfeeding. In all women who have a history of GD, monitoring of TSH receptor antibodies (TRAb) is strongly recommended during pregnancy, and if elevated, foetal monitoring and assessment of thyroid function in the neonate are required. Of note, RAI increases TRAb for up to a year, making this treatment option even less attractive in this patient group. A small amount of ATD is transferred into breast milk but low doses are safe during lactation. Routine periodic thyroid function testing is recommended in remission to detect postpartum GD recurrence. We present our approach to the Clinical Question ‘How to manage GD in women of childbearing potential?’
- 22 February 2022
- Published by Wiley in Clinical Endocrinology
- Vol. 98 (5) , 643-648
Open AccessHow to manage Graves’ disease in women of childbearing potential
The management of Graves’ disease (GD) in women of childbearing potential has multiple specific complexities. Many factors are involved, which differ at the various stages from preconception, conception, first trimester, later pregnancy, postpartum and lactation, with both maternal and foetal considerations. The incidence and significance of the risks incurred from antithyroid drugs (ATDs) in pregnancy have been re‐evaluated recently and must be balanced against the risks of uncontrolled hyperthyroidism during childbearing years. Contraception is advised until hyperthyroidism is controlled. ATD cessation should be considered in those who are well controlled on low dose therapy before conception and in early pregnancy. Advice on iodine supplementation does not generally differ in those with GD. Radioiodine (RAI) is contraindicated from 6 months preconception until completion of breastfeeding. In all women who have a history of GD, monitoring of TSH receptor antibodies (TRAb) is strongly recommended during pregnancy, and if elevated, foetal monitoring and assessment of thyroid function in the neonate are required. Of note, RAI increases TRAb for up to a year, making this treatment option even less attractive in this patient group. A small amount of ATD is transferred into breast milk but low doses are safe during lactation. Routine periodic thyroid function testing is recommended in remission to detect postpartum GD recurrence. We present our approach to the Clinical Question ‘How to manage GD in women of childbearing potential?’
- Open Access
- 28 December 2021
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (1) , e17-e18
Response to Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126
We thank Dr. Thiruvenkatarajan et al. (1) for their interest in our article (2). In developing the reference interval for blood ketone concentrations, we used t
- 28 December 2021
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (1) , e17-e18
Open AccessResponse to Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126
We thank Dr. Thiruvenkatarajan et al. (1) for their interest in our article (2). In developing the reference interval for blood ketone concentrations, we used t
- 26 October 2021
- Published by Wiley in Clinical Endocrinology
- Vol. 96 (4) , 549-557
Body mass index is inversely associated with capillary ketones at the time of colonoscopy: Implications for SGLT2i use
Objective: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been associated with diabetic ketoacidosis at the time of colonoscopy. This study aimed to identify factors associated with ketone concentrations in SGLT2i‐treated type 2 diabetes compared with non‐SGLT2i‐treated diabetes, and those with impaired fasting glycaemia (IFG) and normoglycaemia.Design: Cross‐sectional, multicentre, observational study June–December 2020 in four Australian tertiary hospitals.Participants: Capillary glucose and ketones were measured in people undergoing colonoscopy: 37 SGLT2i‐treated and 105 non‐SGLT2i‐treated type 2 diabetes, 65 IFG and 151 normoglycaemia.Measurements: Body mass index (BMI), age, glucose, fasting duration and where relevant, HbA1c and time since last SGLT2i dose.Results: In SGLT2i‐treated diabetes, BMI (ρ = −0.43 [95% confidence interval: −0.67, −0.11]) and duration since last SGLT2i dose (ρ = −0.33 [−0.60, 0.00]) correlated negatively with increasing ketones, but there was no correlation with fasting duration. In non‐SGLT2i‐treated diabetes, BMI correlated negatively (ρ = −0.24 [−0.42, −0.05]) and fasting duration positively (ρ = 0.26 [0.07, 0.43]) with ketones. In IFG participants, only fasting duration correlated with ketones (ρ = 0.28 [0.03, 0.49]). In normoglycaemic participants, there were negative correlations with BMI (ρ = −0.20 [−0.35, −0.04]) and fasting glucose (ρ = −0.31 [−0.45, −0.15]) and positive correlations with fasting duration (ρ = 0.20 [0.04, 0.35]) and age (ρ = 0.19 [0.03, 0.34]). Multiple regression analysis of the entire cohort showed BMI, age and fasting glucose remained independently associated with ketones, but in SGLT2i‐treated participants only BMI remained independently associated.Conclusions: In SGLT2i‐treated diabetes, lower BMI was a novel risk factor for higher ketones precolonoscopy. Pending larger confirmatory studies, extra vigilance for ketoacidosis is warranted in these people.
- 26 October 2021
- Published by Wiley in Clinical Endocrinology
- Vol. 96 (4) , 549-557
Body mass index is inversely associated with capillary ketones at the time of colonoscopy: Implications for SGLT2i use
Objective: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been associated with diabetic ketoacidosis at the time of colonoscopy. This study aimed to identify factors associated with ketone concentrations in SGLT2i‐treated type 2 diabetes compared with non‐SGLT2i‐treated diabetes, and those with impaired fasting glycaemia (IFG) and normoglycaemia.Design: Cross‐sectional, multicentre, observational study June–December 2020 in four Australian tertiary hospitals.Participants: Capillary glucose and ketones were measured in people undergoing colonoscopy: 37 SGLT2i‐treated and 105 non‐SGLT2i‐treated type 2 diabetes, 65 IFG and 151 normoglycaemia.Measurements: Body mass index (BMI), age, glucose, fasting duration and where relevant, HbA1c and time since last SGLT2i dose.Results: In SGLT2i‐treated diabetes, BMI (ρ = −0.43 [95% confidence interval: −0.67, −0.11]) and duration since last SGLT2i dose (ρ = −0.33 [−0.60, 0.00]) correlated negatively with increasing ketones, but there was no correlation with fasting duration. In non‐SGLT2i‐treated diabetes, BMI correlated negatively (ρ = −0.24 [−0.42, −0.05]) and fasting duration positively (ρ = 0.26 [0.07, 0.43]) with ketones. In IFG participants, only fasting duration correlated with ketones (ρ = 0.28 [0.03, 0.49]). In normoglycaemic participants, there were negative correlations with BMI (ρ = −0.20 [−0.35, −0.04]) and fasting glucose (ρ = −0.31 [−0.45, −0.15]) and positive correlations with fasting duration (ρ = 0.20 [0.04, 0.35]) and age (ρ = 0.19 [0.03, 0.34]). Multiple regression analysis of the entire cohort showed BMI, age and fasting glucose remained independently associated with ketones, but in SGLT2i‐treated participants only BMI remained independently associated.Conclusions: In SGLT2i‐treated diabetes, lower BMI was a novel risk factor for higher ketones precolonoscopy. Pending larger confirmatory studies, extra vigilance for ketoacidosis is warranted in these people.
- 1 October 2021
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 24 (4) , 581-590
The Utility of Prophylactic Zoledronic Acid in Patients Undergoing Lung Transplantation
- 1 October 2021
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 24 (4) , 581-590
The Utility of Prophylactic Zoledronic Acid in Patients Undergoing Lung Transplantation
- 25 April 2021
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (6) , e124-e126
Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes
- 25 April 2021
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (6) , e124-e126
Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes